Translational Psychiatry

Journal Title

Translational Psychiatry

TRANSL PSYCHIAT

ISSN / eISSN

2158-3188 / 2158-3188

Aims and Scope

Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

Subject Area

PSYCHIATRY

CiteScore

10.20 View Trend

CiteScore Ranking

Category	Quartile	Rank
Medicine - Psychiatry and Mental Health	Q1	#36/531
Medicine - Biological Psychiatry	Q1	#6/47
Medicine - Cellular and Molecular Neuroscience	Q1	#13/90

Web of Science Core Collection

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

Category (Journal Citation Reports 2023)	Quartile
PSYCHIATRY - SCIE	Q1

H-index

65

Country/Area of Publication

UNITED STATES

Publisher

Springer Nature

Year Publication Started

2011

Annual Article Volume

498

Open Access

YES

Contact

CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW